Accelerating Novel Diagnostic Solutions for Alzheimer’s Disease
The ALZpath difference
ALZpath provides diagnostic tools and expertise in Alzheimer’s Disease. We believe that with timely and accurate diagnosis, targeted treatments, and support it is possible to improve outcomes for patients and those living with risk of Alzheimer’s Disease.
Blood-based biomarker (pTau217) for the early
diagnosis of Alzheimer’s Disease
Innovative diagnostic tools for various contexts of use
Track over time the impact of a treatment or the progression of an individual’s Alzheimer’s Disease
Clinical trial and emerging therapies screening and stratification
A timely and accessible diagnosis
Our novel and proprietary diagnostic blood test is the only commercially available test for phosphorylated tau 217 (pTau217). We offer an approach to diagnosis that is:
- Simple
- Accessible
- Timely
- Cost-effective
- Less invasive
pTau217 can be measured in blood to gain valuable information about what is occurring in the brain. This powerful diagnostic tool can identify key markers of Alzheimer’s Disease in the brain prior to the onset of cognitive symptoms.
Chad Holland Announced as ALZpath President and CEO
July 9, 2024
ALZpath announces the board’s appointment of Chad Holland as the company’s new president and CEO. The appointment comes after Venkat Shastri, company co-founder and former CEO, chose to step aside to take on an advisory role. Holland brings a deep skillset in commercialization, business development, and fundraising, perfectly positioning him to accelerate the company’s growth.
New Study in JAMA Affirms High Diagnostic Accuracy of ALZpath’s pTau217 Test
January 22, 2024
The ALZpath pTau217 assay has been featured in a crucial evaluation of biomarkers of Alzheimer’s disease pathology published today in JAMA Neurology. Dr. Ashton and colleagues demonstrated that our ALZpath pTau217 assay can accurately identify and longitudinally monitor Alzheimer’s disease pathology, including in preclinical stages, comparable to CSF and PET tests. Tools like the ALZpath pTau217 test will be vital to screening and treating patients at scale, optimizing outcomes, and reducing long-term costs.
ALZforum Spotlights the Clinical Launch of ALZpath pTau217
December 1, 2023
We are thrilled that ALZforum highlighted the clinical launch of ALZpath pTau217 in their article last week. This feature included key contributions from our esteemed Chief Scientific Officer, Andreas Jeromin.
ALZpath is immensely proud of the contributions made by Andreas Jeromin and the entire team, and we’re excited to witness the impact of ALZpath pTau217 in the quest to better understand and manage Alzheimer’s disease.
